Ginseng focus trial halted early – little to go on
NCT ID NCT07255755
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a single 200 mg dose of American Ginseng (Cereboost) could improve attention and brain function in healthy young adults aged 18-40. Participants completed cognitive tests and gave blood samples over 6 hours. However, the trial was terminated early and only enrolled 27 people, so no reliable conclusions can be drawn.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- American Ginseng extract (Cereboost)
- What this could lead to
- If it worked, this could suggest a natural supplement for short-term attention or focus in healthy people.
- What could go wrong
- The trial was terminated early with only 27 participants, so results are incomplete and unreliable. Any benefits would be small and temporary, not a treatment for any condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
27 people
The number who actually took part.
- Started
-
Dec 2025
- Finished
-
Jun 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 40 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: To be eligible for inclusion, the Participant must fulfil all the following criteria: 1. Be able to give written informed consent. 2. Be between 18-40 years, inclusive. 3. Depression Anxiety and Stress Scale scores (DASS-21): 1. Depression ≤9 2. Anxiety ≤7 3. Stress ≤14 4. Willing to refrain from alcohol consumption 24-hours prior to assessment visits. 5. Willing to refrain from caffeine consumption (including but not limited to energy drinks, soda, coffee…) on the morning of the assessment visit. 6. Non-smokers and non-vapers 7. Willing to consume the Study Product (SP). 8. Willing to attend the study visit in an overnight fasted state, having followed a low-polyphenol diet for 48 h. 9. Fluent in written and spoken English Exclusion Criteria: Participants will be excluded from the study if they meet any of the following criteria: 1. Participants who are pregnant or wish to become pregnant during the study or who are lactating and/or currently breastfeeding. 2. Has food allergies or other issues with foods that would preclude intake of the Study Products. 3. Not willing to consume gelatine from bovine/porcine source 4. Has a BMI ≤18.5 or ≥30kg/m2 5. Blood pressure \>140/90 mmHg 6. Has any significant acute or chronic coexisting health conditions that would prevent them from fulfilling the study requirements, put the participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history and routine laboratory test results. 7. Excluded health conditions include: 1. Cognitive disorders in the past 12 months. 2. Current or past history of a major neuropsychiatric disorder, including: bipolar disorder, schizophrenia and schizotypal personality disorder 3. Current or past history of a major neurological condition. 4. Gastrointestinal disorders (e.g. IBS/IBD) 5. ADHD (attention deficit hyperactivity disorder) 6. Learning disabilities and difficulties 7. Current, uncorrected, vision or hearing impairment 8. Current or recent use of a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results. Prohibited medications include: 1. Anti-psychotics 2. Anti-coagulants (including Warfarin) 3. Anti-platelets (including Aspirin and Clopidogrel) 4. Sedatives 5. Monoamine Oxidase Inhibitors (MAOIs) 9. Taking any dietary supplements and unwilling to stop for two weeks prior to and for the duration of participation in the study 10. Current or history of drug or alcohol abuse 11. Current or history of: HIV, kidney disease, liver or biliary disorders, cancer, cardiovascular disease, pulmonary disease (chronic respiratory trouble) 12. Planned surgery within 2 weeks of their participation in the study 13. Do not agree to the GP being contacted about participation and screening results 14. Participated in any other cognitive trials within the last month
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Attention are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Quadram Insitute Clinical Research Facility
Norwich, Norfolk, NR4 7UQ, United Kingdom
-
University of East Anglia
Norwich, Norfolk, NR4 7UQ, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- 150,000 children to be tracked from birth to old age in massive health study
- Can beef power firefighter recovery?
- Can pork protein speed recovery after firefighting?
- Can yoga calm anxious minds and sharpen focus?
- Can video games keep your brain sharp? trial pits xbox against Paper-and-Pencil training
- Can a dead probiotic revive aging brains?